Tirosint Shortage: What Providers and Prescribers Need to Know in 2026

Tirosint Shortage: What Providers and Prescribers Need to Know in 2026

As a provider managing patients with hypothyroidism or thyroid cancer, you may be fielding increasing calls from patients who can't fill their Tirosint prescriptions. While Tirosint (Levothyroxine Sodium capsules, IBSA Pharma) is not formally listed on national shortage databases, real-world availability has been inconsistent — creating practical challenges for clinical practice.

This briefing covers the current state of Tirosint availability, the factors driving access issues, prescribing considerations, cost landscape, and resources to support your patients and practice.

Current Status and Timeline

As of early 2026, Tirosint is not listed on the FDA Drug Shortage Database or the ASHP Drug Shortage Resource Center. IBSA Pharma has not reported manufacturing disruptions for either Tirosint capsules or Tirosint-SOL oral solution.

However, the practical picture tells a different story. Many retail pharmacies — particularly large chains — do not consistently stock Tirosint due to its relatively low prescription volume compared to generic Levothyroxine tablets. This "effective shortage" at the pharmacy level has been a persistent issue rather than an acute event.

Key Timeline Points

• 2020: Lannett launched the first authorized generic Levothyroxine Sodium capsule (same gel cap formulation as Tirosint)
• Early 2025: Generic Levothyroxine tablet supply constraints reported (Kaiser Permanente issued patient notifications), increasing demand for alternative formulations
• July 2024: YARAL Pharma became the sole authorized generic Tirosint capsule supplier
• 2026: No formal shortage, but pharmacy-level availability remains inconsistent

Prescribing Implications

When patients report difficulty finding Tirosint, several prescribing considerations come into play:

Why Patients Are on Tirosint

Understanding why a patient was prescribed Tirosint — rather than standard Levothyroxine tablets — is essential before considering any change:

• Absorption concerns: Patients with celiac disease, lactose intolerance, inflammatory bowel disease, or gastric bypass may have been switched to Tirosint for its superior absorption profile
• Filler/dye sensitivity: Tirosint contains only gelatin, glycerin, and water — no lactose, gluten, dyes, or sugar. Patients with sensitivities to tablet excipients may not tolerate alternatives
• Medication interactions: The gel cap formulation may be less susceptible to absorption interference from calcium, iron, PPIs, and coffee compared to tablets
• TSH instability: Patients with previously difficult-to-control TSH levels may have stabilized on Tirosint

Switching Considerations

If a patient must switch from Tirosint to another Levothyroxine product:

• Start with the same mcg dose of the alternative product
• Recheck TSH in 6-8 weeks after the switch
• Document the reason for the switch in the medical record
• Consider the authorized generic (YARAL Pharma Levothyroxine Sodium Capsules) as the closest 1:1 substitution
• Monitor for symptoms of under- or over-replacement (fatigue, weight changes, palpitations, heat/cold intolerance)

For more on alternative medications, see our clinical guide to Tirosint alternatives.

Current Availability Picture

The availability landscape for Tirosint and related products in 2026:

• Tirosint Capsules (brand): Available but inconsistently stocked at retail pharmacies. More reliably available through mail-order and specialty pharmacies.
• Tirosint-SOL (oral solution): Available in 15 strengths. May be available at pharmacies that don't carry capsules. Offers additional dosing precision (37.5 mcg, 44 mcg, 62.5 mcg strengths).
• Authorized Generic Capsules (YARAL Pharma): Same gel cap formulation as brand Tirosint. Availability may vary.
• Generic Levothyroxine Tablets: Widely available from multiple manufacturers, though some supply constraints were noted in early 2025.

Cost and Access Landscape

Cost remains a significant barrier for Tirosint patients:

• Brand Tirosint cash price: $150-$250/month (30 capsules)
• With Copay Savings Card: As low as $25/month (30-day) or $60 (90-day)
• Tirosint Direct (mail order): $65/month (30-day) or $170 (90-day)
• IBSA Patient Assistance Program: Free medication for eligible patients based on income and insurance status
• Generic Levothyroxine tablets: $4-$20/month

Insurance coverage varies significantly. Most plans place Tirosint on Tier 3 (preferred brand) or higher, and many require prior authorization with documentation of medical necessity (e.g., documented absorption issues, allergy to tablet excipients). Step therapy requiring a trial of generic Levothyroxine tablets is common.

Tools and Resources for Your Practice

Several resources can help you and your patients navigate Tirosint access:

Medfinder for Providers

Medfinder offers a provider-facing tool that checks real-time pharmacy availability for Tirosint and other medications. You can direct patients to search for in-stock pharmacies near them, or use it within your practice to identify fill options before writing a prescription.

IBSA Savings and Assistance Programs

• Tirosint Copay Savings Card: Available for insured and uninsured patients. Download at tirosint.com.
• Tirosint Direct Program: Mail-order option at fixed pricing ($65/month). Bypasses local pharmacy availability issues.
• Patient Assistance Program: Free medication for qualifying patients. Application through tirosint.com or tirosintsol.com.

Prior Authorization Support

When writing prior authorizations for Tirosint, document:

• History of absorption issues or TSH instability on tablets
• Allergy or sensitivity to tablet excipients (dyes, lactose, gluten)
• Relevant GI conditions (celiac disease, IBD, gastric bypass)
• Previous therapeutic failure on generic Levothyroxine tablets

Looking Ahead

The Tirosint availability picture is unlikely to change dramatically in the near term. As a niche brand-name product with a single manufacturer, supply will continue to depend on IBSA Pharma's production capacity and distribution network. The authorized generic through YARAL Pharma provides an additional supply source but doesn't fully resolve pharmacy-level stocking issues.

Providers can best support their patients by:

• Proactively discussing backup options and fill strategies
• Recommending tools like Medfinder for pharmacy availability
• Connecting patients with the Tirosint Direct Program and savings resources
• Pre-authorizing refills with enough lead time to avoid gaps

For a practical workflow guide, see our provider's guide to helping patients find Tirosint.

Final Thoughts

While Tirosint is not in a formal shortage, the gap between availability on paper and availability at the pharmacy counter is real. As prescribers, we can make a meaningful difference by being proactive about fill strategies, keeping patients informed about savings programs, and using tools like Medfinder to bridge the gap between prescription and access.

For additional cost-saving strategies to share with patients, see our provider's guide to saving money on Tirosint.